The Centre of New Technologies invites to a seminar by
Anna Sarnowska, M.D., Ph.D
Head of Translative Platform for Regenerative Medicine, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw
Title: Cell therapy in clinical and preclinical research
Date: December 6th, 2019 at 12 p.m.
Venue: Centre of New Technologies, Banacha 2C,
Lecture Hall 0142 (Ground floor)
Host: prof. Marta B. Wiśniewska
In recent years, we have seen the rapid development of regenerative medicine based on the stem cells application. Over the last years, procedures have been intensively developed to enable effective derivation and cultivation of mesenchymal stem cells (MSCs) for future clinical applications. At the same time, numerous studies have confirmed the therapeutic efficacy of MSCs based on their secretion and immunomodulatory effects although there are still only few diseases where MSC application lead to restore normal function. Unfortunately, the rapid commercialization of such treatment is not always supported by basic knowledge and conducted in accordance with the principles of “evidence-based medicine.” To move regenerative medicine into the realms of mainstream medicine, it should be clearly indicated what has been achieved so far in regenerative medicine, explain to patients the possible therapeutic effect of MSC and treat most stem cell applications as experimental therapies. In order to achieve the main goal of stem cell based therapy – replacing damaged cells with new injected cells, basic research concerning MSC isolation, cultivation or preconditioning procedures before transplantation should be conducted.
Our results show significant differences in phenotype, proliferation rate, CFU-F formation and the number of senescent cells between MSC populations obtained with different methods of isolation. Moreover the method of cell isolation may substantially affect their properties, differentiation abilities and presumably the neuroprotective properties. Therefore the efficiency cannot be the main determinant to choose the method of isolation.
Additionally, our experiments showed that the strongest ability for neuroprotection was provided by freshly isolated cells and the first cohort of migrating MSC cells (passage O). Undifferentiated, SRTF expressing MSC, capable to time-locked proliferation, migration and ultimately to neural differentiation are the most effective in various therapeutic transplantation models. To keep the cells in undifferentiated state culture conditions e.g. oxygen concentration are crucial.
